CryoPort, Inc. (CYRX) shares ended the last trading session 26.7% higher at $7.03. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 47.6% loss over the past four weeks.CryoPort  expects revenues to improve as the year goes on. Revenues from the company's Life Sciences Products group are likely to drive growth. Moreover, it seems that investors are bullish on the fact that the Schall Law Firm, a national shareholder ...

Partnership Will Provide Cell and Gene Therapy Industry with Fully Integrated Logistics and Manufacturing Services for Regenerative Medicine ProductsNASHVILLE, Tenn. and YOKOHAMA, Japan, June 20, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences, and Minaris Regenerative Medicine Co., Ltd. ("Minaris"), a global contract development and manufacturing organization for cell and gene therapies, today announced a strategic partnership ...

LOS ANGELES, June 5, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ: CYRX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.If you are a shareholder who suffered a loss, click here to participate.We also enco ...

财务数据和关键指标变化 - 第一季度总收入低于预期,但公司维持全年收入指引 [9][14] - 商业疗法收入同比增长9%,生物存储/生物服务收入同比增长9% [10][47][48] - 生命科学产品收入低于预期,主要由于MVE生物制冷系统需求下降 [12][17][18][19][20][24][26] 各条业务线数据和关键指标变化 - 商业疗法收入有望在下半年加速增长,得益于新获批的疗法和现有疗法的扩展 [10][11][47][48] - 生物存储/生物服务业务收入持续增长,为公司收入增长提供支撑 [10][47][48] - MVE生物制冷系统销售在全年仍将面临挑战,但预计需求将逐步改善 [12][24][26][39] 各个市场数据和关键指标变化 - 中国市场需求下降是MVE业务疲软的主要原因,但中国市场仅占公司总收入5% [26][51][52][53] - 公司正在采取措施在中国市场提高竞争力,包括在当地制造产品 [51][52][58][59] 公司战略和发展方向及行业竞争 - 公司将继续投资于细胞和基因疗法领域,为这一快速增长的市场提供全面的供应链支持 [13][47][48] - 公司正在采取措施提高运营效率和现金流,包括优化组织架构、裁员、利用低成本共享服务等 [14][37][38][66][67] - 公司保持强大的资产负债表,以支持未来增长 [14] - 传统物流公司如UPS进入医疗领域,但公司与集成商的合作关系仍在持续 [27][28][29] 管理层对经营环境和未来前景的评论 - 公司对下半年收入增长持乐观态度,预计商业疗法和生物存储/生物服务业务将持续增长 [9][10][47][48] - 尽管当前宏观环境充满挑战,但公司有信心实现全年收入指引 [9][46][47][48] - 公司将继续专注于战略重点,扩大客户群、提供创新服务,同时提高运营效率 [134] 问答环节重要的提问和回答 问题1 **Matt Stanton 提问** 询问MVE业务的情况,包括客户需求、订单情况等 [17][23] **Jerrell Shelton 回答** MVE业务受到需求疲软的影响,尤其是中国市场,但预计下半年将逐步改善 [24][26][39] 问题2 **Philip Song 提问** 询问公司能够实现全年指引的关键驱动因素 [46][47] **Jerrell Shelton、Robert Stefanovich 回答** 公司看好商业疗法和生物存储/生物服务业务的增长前景,以及新获批的疗法带来的贡献 [47][48][49] 问题3 **David Larsen 提问** 询问公司的成本优化措施及其对EBITDA的影响 [63][64][65][66][67] **Jerrell Shelton、Robert Stefanovich 回答** 公司正采取多项措施提高运营效率和现金流,包括优化组织架构、裁员、利用共享服务等,预计将在下半年产生积极影响 [66][67][68][69][70][71]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-34632 CRYOPORT, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 88-0313393 (St ...

Q1 2024 Earnings Call May 7, 2024 Forward Looking Statements Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, long-ter ...

Exhibit 99.1 Cryoport Reports First Quarter 2024 Financial Results § Q1 2024 revenue of $54.6 million § 9% year-over-year increase in Commercial Cell & Gene Therapy revenue § 9% year-over-year increase in BioStorage/BioServices revenue § A total of 675 global clinical trials supported as of March 31, 2024 § $242 - $252 million full year 2024 revenue guidance reiterated NASHVILLE, Tennessee, May 7, 2024, - Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life scienc ...

NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will report financial results for the first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter 2024 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be i ...

业绩总结 - Cryoport公司2023财年总收入为2.333亿美元，服务业务收入占比62%[8] - 2023年服务业务收入同比增长33%，Q4增长36%[22] - 2023年总体毛利率为42.6%，较去年43.8%有所下降[24] - 预计2024年全年营收范围为2.42亿至2.52亿美元[14] - 预计2024年毛利率将趋于稳定，随着业务逐步增长[24] 未来展望 - 预计2024年生物制药资金恢复将逐步改善[28] - 预计2024年将有多达9种新疗法获批，为公司带来显著增长[30] - 公司对2024年的增长预期保守，但存在一些潜在上行空间，如新产品快速采用、现有疗法快速增长等[42] - 预计在2024年，细胞和基因领域的批准活动将达到历史最强水平，可能会有9种新疗法推出[58] 市场扩张和并购 - Cryoport在2023年进行了有针对性的投资，与多个合作伙伴建立战略关系，包括收购Bluebird Express和TEC4MED LifeSciences，与Cell and Gene Therapy Catapult network和NMDP BioTherapies等合作，以及与Nippon Express建立战略合作伙伴关系[10] 新产品和新技术研发 - TEC4MED是一家德国公司，提供先进的通信和温度监测系统，正在与SmartPak和SkyTrax项目相互影响和合作[96] - 公司已支持大量异基因疗法产品，占整体产品组合的近30%，并有望继续增长[80]

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -59.38%. A quarter ago, it was expected that this company would post a loss of $0.31 per share when it actually produced a loss of $0.31, delivering no surprise.Over the last four quarters, the company has surpassed consens ...